Keryx' phosphate binder set for filing following impressive Phase III
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals said it anticipates US and European regulatory submissions for Zerenex (ferric citrate; KRX-0502) in the second quarter of 2013, after reporting top-line data showing that a Phase III study investigating the treatment for hyperphosphataemia in end-stage renal disease (ESRD) patients on dialysis met the primary and all key secondary endpoints.